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http:WHAT THIS PAPER ADDS
Midterm outcomes are essential to the debate on whether endovascular (EVAR) or open repair (OR) is to be
preferred for patients with a RAAA. This study showed that 5 years after the primary intervention, EVAR and OR
resulted in similar re-intervention and survival rates. However, in patients who survived their hospital stay the
re-intervention rate was higher for EVAR than for OR. When deciding between these interventions in the acute
setting, caregivers have to balance short-term beneﬁts after EVAR with the lower midterm risk of re-intervention
after discharge for OR.Objective: To compare the midterm re-intervention and survival rates after EVAR and OR for ruptured abdominal
aortic aneurysms (RAAA).
Methods: Observational cohort study including all consecutive RAAA patients between 2004 and 2011 in 10
hospitals in the Amsterdam ambulance region. The primary end point was re-interventions within 5 years of the
primary intervention. The secondary end point was death. The outcomes were estimated by survival analyses,
compared using the logrank test, and subsequently adjusted for possible confounders using Cox proportional
hazard models. Re-interventions were estimated in all patients and in patients who survived their hospital stay.
Results: Of 467 patients with a RAAA, 73 were treated by EVAR and 394 by OR. Five years after the primary
intervention, the rates of freedom from re-intervention were 55% for EVAR (26/73, 95% CI: 41e69%) and 60% for
OR (130/394, 95% CI: 55e66%) (p ¼ .96). After adjustment for age, sex, comorbidity, and pre-operative
hemodynamic stability, the risk of re-intervention was similar (HR 1.01, 95% CI: 0.65e1.55). The survival rates
were 36% for EVAR (45/73, 95% CI: 24e47%) and 38% for OR (235/394, 95% CI: 33e43%) (p ¼ .83). In 297
patients who survived their hospital stay, the rates of freedom from re-intervention were 66% for EVAR (15/54,
95% CI: 52e81%) and 90% for OR (20/243, 95% CI: 86e95%) (p < .01). After adjustment for age and sex, the risk
of re-intervention was higher after EVAR (HR 0.27, 95% CI: 0.14e0.52).
Conclusions: Five years after the primary intervention, endovascular and open repair for ruptured abdominal
aortic aneurysm resulted in similar re-intervention and survival rates. However, in patients who survived their
hospital stay the re-intervention rate was higher for EVAR than for OR.
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Patients with a ruptured aneurysm of the abdominal aorta
(RAAA) can be treated by endovascular (EVAR) or open
repair (OR). To date, no signiﬁcant difference in the 30 day
mortality rate has been reported between these in-
terventions in randomised controlled trials.1e3 For this
reason, midterm outcomes are starting to be of interest in
the debate on whether EVAR or OR is to be preferred for
patients with a RAAA.3e5 Midterm includes the 5 year
period after primary intervention. In elective aortic surgery,
the midterm risk of re-intervention and aneurysm rupture is
662 S.C. van Beek et al.higher after EVAR than after OR.6 Midterm outcomes after
acute intervention may also differ. Therefore, midterm
outcomes may give new insights into the preferred inter-
vention in patients with a RAAA or guide post-intervention
surveillance strategies. In the present study, re-intervention
and survival rates 5 years after EVAR and OR for a RAAA
were compared.
MATERIAL AND METHODS
The present study was an observational cohort study and
reports follow up data from the previously published
Amsterdam Acute Aneurysm (AJAX) trial (ISRCTN 66212637),
which was conducted in the Amsterdam ambulance region.
This ambulance region comprises 10 hospitals and 1.38
million inhabitants.1,7 Between April 2004 and February
2011, all consecutive patients with a RAAA in the region
were registered prospectively and of these, all who under-
went surgical treatment were included in the present study.
Only patients whose demographics or short-term outcome
were unknown were excluded.
In the Amsterdam ambulance region between 2004 and
2011, care was concentrated into three vascular centres with
a 24 hour full emergency vascular service in cooperation
with the seven referring regional hospitals.7 All patients
suspected by the ambulance staff, general practitioner, or a
surgeon in a referring hospital of having a RAAA were
transported to a vascular centre. Only patients admitted to
one of the seven referring hospitals, but who were deemed
unﬁt for transfer, were treated locally. The three vascular
centres treated patients by both EVAR and OR and the seven
referring regional hospitals offered OR only. To assess suit-
ability for EVAR, patients were evaluated with computed
tomographic angiography (CTA). Patients suitable for both
EVAR and OR were consented to be randomised between
the interventions in the AJAX trial. The AJAX trial adhered to
the CONSORT 2010 statement8 and details regarding the
design, primary outcome, sample size, randomisation pro-
cedure and informed consent procedure have been pub-
lished previously.1 After discharge patients had routine
follow up according to local practice. EVAR follow up
included either yearly computed tomographic angiography
(CTA) or duplex ultrasound combined with plain abdominal
x-ray. The follow up and rationale for re-intervention
including the handling of type II endoleaks, were left to
the discretion of the treating physician and were not
standardised in the context of the present study.
The study was conducted in accordance with the principles
of the Declaration of Helsinki and the present report includes
all items recommendedby the STrengthening theReportingof
Observational studies in Epidemiology (STROBE) statement.9End point
The primary end point was re-intervention within 5 years of
the primary intervention. The secondary end point was
death. Re-interventions were deﬁned according to the
reporting standards10 and comprised both surgical and
endovascular procedures. Indications for re-interventionincluded abdominal compartment syndrome, access site
infection, anastomotic aneurysm, re-bleeding, bowel
ischaemia, endograft migration, endoleak (type I e IV), false
aneurysm, graft thrombosis or obstruction, graft infection
including aorto-enteric ﬁstula, incisional hernia including
other abdominal wall complications such as full thickness
dehiscence, ischaemia of lower limbs including major am-
putations and peripheral fasciotomy, secondary aneurysm
rupture, secondary symptomatic aneurysm and symptom-
atic adhesions.
Data collection
Data were collected up to January 2014 using Microsoft
Ofﬁce Access 2003 (Microsoft Corporation, Redmond, WA,
USA) and included ﬁeld limits and multivariate checks.
Dates of death were obtained stepwise from the hospital
registries (1), from the registry of the general practitioner
(2), or from the communal registry of death certiﬁcates (3).
Data regarding re-interventions and their indications were
collected from hospital medical records and the general
practitioners were asked for information on re-interventions
in other hospitals. Patients whose follow up was unknown
were censored in the analysis at the last point of contact.
Data collection for EVAR and OR patients was done in the
same way.
Statistical analysis
Continuous data were described by the median with cor-
responding interquartile range (IQR) because of a skewed
distribution. Baseline characteristics were compared using
the chi-square test and the Mann-Whitney U test (two
sided; a ¼ .05). The re-intervention and survival rates were
estimated by Kaplan-Meier survival analysis and compared
using the logrank test. Re-intervention rates were reported
as freedom from re-intervention with corresponding events
and surrounding 95% conﬁdence intervals (CI). In the
Kaplan-Meier survival analyses of the re-intervention rates,
patients who died were censoed.
Two subgroup analyses were conducted. The ﬁrst sub-
group included patients who survived their hospital stay and
the ﬁrst 30 days after the primary intervention. The second
subgroup included patients from the AJAX trial in whom
treatment allocation was done using randomisation. This
subgroup analysis provided follow up data for all patients
(EVAR n ¼ 57, OR n ¼ 59) included in the AJAX trial and was
analysed according to the intention to treat principle.
Two multivariable Cox proportional hazards models were
developed to assess the association between type of
intervention and re-intervention after adjustment for
possible confounders. The ﬁrst Cox model included all pa-
tients and the association between type of intervention and
re-intervention was adjusted for age, sex, comorbidity, and
haemodynamic stability based on pre-operative cardiopul-
monary resuscitation and lowest in hospital systolic blood
pressure. To include all patients in this analysis, an impu-
tation procedure was done for missing data, of which de-
tails have been published previously.7 The second Cox
Figure 1. Flowchart of inclusion in all 467 patients (main analysis), in 297 patients who survived their hospital stay (subgroup 1), and in 116
patients randomised in the AJAX trial (subgroup 2).
Midterm Re-interventions and Survival After EVAR 663model included patients of the ﬁrst subgroup who survived
their hospital stay and the association between type of
intervention and re-intervention was adjusted for age and
sex.
RESULTS
Between 2004 and 2011, 539 patients with a RAAA were
admitted to one of the 10 hospitals in the Amsterdam
ambulance region. Six patients whose demographics or
outcome were unknown and 66 patients without surgical
intervention were excluded from the analysis (Fig. 1). Of
467 patients included in the analysis, 407 were treated in
the vascular centres and 60 in the referring hospitals.
The baseline characteristics are shown per type of
intervention in Table 1. Patients treated with EVAR showed
a tendency towards higher pre-operative systolic blood
pressure (SBP) (p ¼ .07), and required less pre-operative
cardiopulmonary resuscitation (CPR). Five years after the
primary intervention, the overall survival rate was 38%
(280/467, 95% CI: 33e43%) and the median follow up wasTable 1. Baseline characteristics.
Original data
EVAR
n ¼ 73
OR
n ¼ 394
Age, median (IQR) 76 (69e80) 76 (69e82)
Female sex 12% (9/73) 20% (80/394)
Cardiac comorbidity 48% (35/73) 42% (158/379)
Pulmonary comorbidity 27% (20/73) 20% (76/376)
Renal comorbidity 10% (7/73) 12% (45/377)
Cerebrovascular comorbidity 15% (11/73) 15% (58/378)
CPR 4% (3/73) 12% (45/374)
SBP, median (IQR) 90 (75e129) 90 (69e125)
CPR ¼ cardiopulmonary resuscitation; SBP ¼ lowest in hospital systol
a Mann-Whitney test.
b Chi-square statistic.2.2 years (interquartile range 0.0e5.0 years). Eighteen pa-
tients (3 for EVAR, 15 for OR) were lost to follow up and
censored at the last point of contact. Fifty-eight patients
received the Talent endograft (Medtronic AVE Europe),
seven patients the Endurant endograft (Medtronic BV,
Heerlen), and the remaining eight patients received another
or unknown endograft.
All patients
Five years after the primary intervention, the rates of
freedom from re-intervention were 55% for EVAR (26/73,
95% CI 41e69%) and 60% for OR (130/394, 95% CI: 55e
66%) (p ¼ .96, Fig. 2A). After multivariate adjustment for
possible confounders, the risk of re-intervention was similar
after EVAR and OR (HR 1.01, 95% CI: 0.65e1.55, Table 2).
The survival rates after 5 years were 36% for EVAR (45/73,
95% CI: 24e47%) and 38% for OR (235/394, 95% CI: 33e
43%) (p ¼ .83, Fig. 3).
After EVAR, during a follow up of 180.3 person years,
there were 45 re-interventions in 26 of 73 patients. SixteenImputed data
p Missing data EVAR OR
.70a 0 NI NI
.11b 0 NI NI
.32b 3% (15/467) NI 42% (165/394)
.17b 4% (18/467) NI 20% (80/394)
.57b 4% (17/467) NI 12% (47/394)
.95b 3% (16/467) NI 15% (60/394)
.05b 4% (20/467) NI 13% (51/394)
.07a 11% (50/467) 90 (76e126) 90 (68e123)
ic blood pressure in mmHg; NI ¼ not imputed.
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664 S.C. van Beek et al.patients had one re-intervention, seven patients had two,
and three patients had three or more re-interventions. The
most frequent indications for in hospital re-intervention
were bowel ischaemia (5/22) and endoleak (4/22), and for
re-intervention after discharge were endoleak (6/23) and
graft infection (5/23) (Table 3). Eight of 45 (18%) re-
interventions were endovascular. Of note, in nine patients
a conversion to OR during the primary intervention was
necessary based on access problems (n ¼ 4), endoleak type
I (n ¼ 2), endoleak type III (n ¼ 2), and failed deployment
(n ¼ 1). Because conversion happened during the primary
intervention, they were not included in the present analysis.
After OR during a follow up of 927.4 person years, there
was a total number of 224 re-interventions in 130 of 394
patients. Seventy-eight patients had one re-intervention, 27
had two, and 25 patients had three or more re-
interventions. The most frequent indications for in hospi-
tal re-intervention were re-bleeding (49/195), bowel
ischaemia (48/195), and ischaemia of lower limbs (42/195),
and for re-intervention after discharge were graft infection
(7/29) and incisional hernia (6/29) (Table 3). Ten of 224 re-
interventions (4%) were endovascular.
Subgroup analysis of discharged patients
Of 467 patients included in the main analysis, 54 of 73
patients survived their hospital stay after EVAR and 243 of
394 patients survived their hospital stay after OR. These 297
patients were further studied in the ﬁrst subgroup including
the patients who survived their hospital stay (Fig. 1). In
patients who survived their hospital stay, the rates of
freedom from re-intervention were 66% for EVAR (15/54,
95% CI: 52e81%), and 90% for OR (20/243, 95% CI: 86e
95%) (p < .01, Fig. 2B). After multivariate adjustment for
possible confounders, the risk of re-intervention was lower
after OR (HR 0.27, 95% CI: 0.14e0.52, Table 2). The overall
survival analysis in these patients is reported as an online
supplement (Fig. S1, online supplement).
Subgroup analysis of randomised patients
Of 467 patients included in the main analysis, 113 were also
randomised between EVAR and OR in the AJAX trial and
were further studied in this second subgroup (Fig. 1).
Because of the intention to treat principle, three patients
with a discharge diagnosis other than RAAA were also
included in the AJAX trial and therefore added to this
subgroup. The baseline data of the AJAX trial have been
published previously.1 The rates of freedom from re-
intervention were 52% for EVAR (22/57, 95% CI 37e68%)
and 59% for OR (20/59, 95% CI 45e74%) (p ¼ .71, Fig. 2C).
The overall survival analysis in these patients is reported as
an online supplement (Fig. S2, online supplement).
DISCUSSION
The present study in patients with a ruptured abdominal
aortic aneurysm shows that 5 years after the primary
intervention the re-intervention and survival rates for
endovascular and open repair are similar. In patients who
Table 2. Multivariate Cox regression models to assess the association between type of intervention (endovascular versus open repair) and
re-intervention in all patients and in the subgroup of patients who survived their hospital stay.
All patientsa Patients who survived their hospital stayb
Hazard ratio (95% CI) Hazard ratio
Age <69 (n ¼ 114) Reference category NI
69e76 (n ¼ 117) 1.35 (0.87e2.11)
76e80 (n ¼ 105) 1.37 (0.86e2.18)
>80 (n ¼ 131) 0.85 (0.52e1.39)
Age per year NI 0.95 (0.92e0.99)c
Female sex 1.09 (0.72e1.65) 0.98 (0.38e2.52)
Cardiac comorbidity 1.13 (0.81e1.58) NI
Pulmonary comorbidity 1.01 (0.67e1.52) NI
Renal comorbidity 1.01 (0.59e1.73) NI
Cerebrovascular comorbidity 0.83 (0.51e1.36) NI
CPR 1.47 (0.84e2.58) NI
SBP <70 (n ¼ 112) Reference category NI
70e90 (n ¼ 101) 1.38 (0.82e2.32)
90e125 (n ¼ 137) 1.28 (0.78e2.11)
>125 (n ¼ 117) 0.71 (0.41e1.22)
Open repair 1.01 (0.65e1.55) 0.27 (0.14e0.52)c
CPR ¼ cardiopulmonary resuscitation; SBP ¼ lowest in hospital systolic blood pressure in mmHg; CI ¼ conﬁdence interval; NI ¼ not
included.
a The model included 467 patients and 156 events. Age and SBP were categorised because of non-linearity.
b The model included 297 patients and 35 events.
c p < .05.
Midterm Re-interventions and Survival After EVAR 665survive their hospital stay the re-intervention rate for EVAR
is higher than for OR.
Indications for re-intervention
Some clear observations can be made from the indications
for re-intervention (Table 3). Comparing EVAR and OR,
there appears to be a beneﬁt for EVAR with regard to re-
bleeding. However, the numbers are small and therefore
power is limited for this comparison. In patients whose
indication for ﬁrst re-intervention was re-bleeding, bowel or
lower limb ischaemia, the mortality rate was 52% (46/88)Figure 3. KaplaneMeier estimates of the overall survival during
the 5 year follow up in all patients.emphasising the importance of these complications. The
number of re-interventions for graft infection were signiﬁ-
cant after both EVAR (6/45) and OR (12/224). The most
likely explanation is the high number of bowel ischaemia
related problems leading to contaminated abdomen.
The numbers of secondary ruptures (n ¼ 0) or symp-
tomatic aneurysms (n ¼ 3) were low after both EVAR and
OR. This is surprising considering the rate of secondary
rupture after elective EVAR. Possibly, follow up was too
short and ruptures will occur later in this cohort. Another
explanation is that secondary ruptures were only consid-
ered an event when re-intervention was performed. To
illustrate this, one patient had a secondary rupture veriﬁed
through autopsy but was not treated surgically. Finally,
patients might have died from a secondary rupture without
the authors’ knowledge. Cause of death was considered to
be unreliable because of a very low number of autopsies.
Confounding
In the Amsterdam ambulance region, patients received
treatment based on the possibility of being able to trans-
port the patient to a vascular centre, suitability for EVAR,
and randomisation in the AJAX trial. In general, haemody-
namically unstable patients had open repair whereas hae-
modynamically stable patients had EVAR. The potential
problem of confounding was addressed in two ways, First,
using multivariate adjustment (Table 2), and, second, using
randomisation by further studying patients who had been
included in the AJAX trial (subgroup 2). The results of both
methods conﬁrm the conclusions of the main analysis that
re-intervention and survival rates are similar, but that pa-
tients who survive their hospital stay have a higher re-
intervention rate after EVAR.
Table 3. Indications for re-intervention after EVAR and OR.
In hospital After discharge
EVAR
(total number ¼ 22)
OR
(total number ¼ 195)
EVAR
(total number ¼ 23)
OR
(total number ¼ 29)
Abdominal compartment syndrome 9% (2) 6% (11) 4% (1) 0
Access site infection 5% (1) 1% (2) 0 7% (2)
Anastomotic aneurysm 0 0 0 0
Re-bleeding 9% (2) 25% (48) 0 3% (1)
Bowel ischaemia 23% (5) 25% (49) 13% (3) 17% (5)
Endograft migration 9% (2) 0 9% (2)a 0
Endoleak 18% (4)b 0 22% (5)c 0
False aneurysm 0 0 9% (2) 0
Graft thrombosis or obstruction 0 0 9% (2) 3% (1)
Graft infection 5% (1) 3% (5) 22% (5) 24% (7)d
Incisional hernia 5% (1) 9% (18) 13% (3) 21% (6)
Lower limb ischaemia 14% (3) 22% (42) 0 7% (2)
Secondary ruptured aneurysm 0 0 0 0e
Secondary symptomatic aneurysm 0 0 0 3% (1)
Symptomatic adhesions 0 1% (2) 0 14% (4)
Other 5% (1) 4% (8) 0 0
Unknown 0 5% (10) 0 0
CI ¼ 95% conﬁdence interval.
a One migration in combination with type I endoleak.
b Four type I endoleaks.
c Two type I endoleaks, three type II endoleaks.
d Two in combination with secondary rupture, one aorto-enteric ﬁstula.
e One patient with secondary rupture veriﬁed by autopsy without re-intervention.
666 S.C. van Beek et al.A limitation of the multivariable analyses is that there is a
risk of residual confounding. Moreover, in the hazard plot a
similar pattern to Figure 2A was seen; during the in hospital
period there were fewer re-interventions after EVAR and
during follow up there were fewer re-interventions after
OR. In this way, the risk of re-intervention after both in-
terventions was balanced in ratio, whereas the hazard plot
was a bit more nuanced. The limitation of the AJAX trial is
that the number of patients included was quite low for
midterm outcomes and the results were therefore statisti-
cally not signiﬁcant.Midterm outcomes
Most studies comparing EVAR and OR for RAAA focus on
short-term outcomes, and only ﬁve studies11e15 have so far
reported midterm outcomes. The present study expands on
these studies by prospective patient identiﬁcation, by multi-
centre design representing 10 hospitals from one ambu-
lance region, and by subgroup analysis with randomised
treatment allocation. Several conclusions can be drawn by
interpreting the present results in light of previous studies.
It is known that in elective aortic surgery, the midterm
risk of re-intervention is higher after EVAR than after OR.6 In
agreement with a previous study,13 the present study shows
that there is no difference in re-intervention rates after an
acute intervention. Because the present study (n ¼ 73) and
the previous study (n ¼ 62) included limited numbers of
patients treated by EVAR, more data are required before
deﬁnite conclusions can be drawn. An interesting observa-
tion from both these studies is that during the in hospitalperiod there were fewer re-interventions after EVAR and
during follow up there were fewer re-interventions after OR
(Fig. 2A).
The present results conﬁrm previous results that in pa-
tients who survive their hospital stay the re-intervention
rate is higher after EVAR than after OR (Fig. 2B).13,15 This
conclusion echoes the results after elective aortic surgery.6
It was not recorded whether the indications for re-
intervention were found by routine follow up or by an
acute event. For this reason, no deﬁnite conclusions could
be drawn about the need for routine follow up after EVAR
for RAAA.
The overall survival rate of all patients in the present
study (38%, 95% CI: 34e43%) corresponds with a previously
reported 5 year survival of 44% (99% CI: 40e47%).11 This
indicates that the 5 year survival after RAAA is low; around
40%.
In the present study, results regarding the midterm sur-
vival after EVAR and OR were conﬂicting. In all patients, the
survival rates 5 years after the primary intervention were
similar for EVAR and for OR (Fig. 3). In patients who sur-
vived their hospital stay, there was a conspicuously higher
survival rate for OR (Fig. S1, online supplement). Conversely,
the subgroup analysis in the AJAX trial showed similar
survival rates for both interventions in all patients and in
patients who survived their hospital stay (Fig. S2, online
supplement). The same conﬂicting results can be found on
assessing the outcomes of previous studies. One study13
reported similar survival rates, whereas other studies re-
ported lower survival rates for EVAR.11,12,14,15 It appears
probable that patient selection for EVAR signiﬁcantly
Midterm Re-interventions and Survival After EVAR 667inﬂuences these midterm survival rates. Because rando-
mised treatment allocation adjusts for this patient selec-
tion, the results of the subgroup analysis in the AJAX trial
guide us towards the conclusion that the midterm survival
rates for EVAR and for OR are comparable.
Finally, the 5 year re-intervention rate after discharge for
EVAR of 34% (95% CI: 19e48%) in the present study was
high compared with the 6 year re-intervention rate for
EVAR of 30% in the Dutch Randomized Endovascular
Aneurysm Repair trial.16 The use of aorto-uni-iliac endog-
rafts could offer an explanation, although no studies have
demonstrated that these endografts carry a higher risk of
re-intervention. On the contrary, studies addressing this
issue in elective aortic surgery have reported comparable
outcomes in aorto-uni-iliac and bifurcated endografts after
multivariate adjustment for patient selection.17,18 A more
plausible explanation is that time is limited for planning the
intervention and sizing the endograft, leading to migration
or endoleaks. Moreover, sizing of the endograft may be
affected by the CT scan of hypovolaemic patients showing a
smaller aorta.
Preferred intervention
The present study adds evidence to the debate on whether
EVAR or OR is to be preferred for patients with a RAAA. The
randomised trials reported similar short-term survival rates
for both EVAR and OR.4 EVAR appears to be beneﬁcial on
secondary outcomes such as less blood loss, less need for
mechanical ventilation and temporary dialysis, a shorter
intensive care and hospital stay, and more patients being
discharged home.1,3 In a direct comparison of costs after 30
days between EVAR and OR in the AJAX trial, EVAR was
more expensive.19 In a comparison of costs after 30 days
between the endovascular and open strategy in the
IMPROVE trial, costs were comparable.3 This indicates that
EVAR is more expensive than OR, but that a treatment
strategy offering both EVAR and OR is not more expensive
than a treatment strategy including only OR. With the re-
sults of the present study in mind, when deciding between
EVAR and OR in the acute setting, caregivers have to bal-
ance the short-term beneﬁt of secondary outcomes after
EVAR with the lower midterm risk of re-intervention after
discharge for OR. In future, it is to be expected that new
endografts will improve midterm outcomes after EVAR.
Limitations
A limitation of the present study was that complications not
requiring surgical intervention were not included. For
example, an incisional hernia in a patient who was
considered to be unﬁt for re-intervention was not included.
Hence, the re-intervention incidence rates do not reﬂect the
true incidence of the complications.
There are also some limitations to the external validity of
the present results. Although the outcomes after EVAR are
restricted to aorto-uni-iliac endografts, in elective aortic
surgery comparable outcomes in aorto-uni-iliac and bifur-
cated endografts have been reported.17,18 In general,indications for re-intervention vary between hospitals and
over time. As mentioned before, the number of patients
treated by EVAR was low (n ¼ 73). The sample size of the
present study was based on the AJAX trial,1 and therefore
only a post hoc power calculation could be done. Consid-
ering the re-intervention rate of 40% after OR and 73 pa-
tients treated with EVAR, the present study had 80% power
to pick up 5 year re-intervention rates after EVAR of <18%
or of >64% (2 sided signiﬁcance level a ¼ .05, b ¼ .20). This
clearly demonstrates that the present study was under-
powered, and that more studies are needed to conﬁrm a
smaller difference in re-intervention rates.
Of those patients evaluated with a CTA in the Amsterdam
ambulance region, only 49% were considered to have aorto-
iliac anatomy suitable for EVAR.20 This is rather low
compared with the suitability rate of 64% in the IMPROVE
trial.3 Caregivers in the Amsterdam region mostly adhered
to the instructions for use (IFU) because few data or
guidelines are available on the use of endografts outside
the IFU. In elective aortic repair, patients treated outside
the IFU have a higher risk of adverse events.21 For this
reason, the midterm re-intervention rates in the Amsterdam
region were probably low compared with hospitals pushing
the anatomical limits of EVAR for RAAAs.
Conclusions
Five years after the primary intervention, endovascular and
open repair for a ruptured abdominal aortic aneurysm
resulted in similar re-intervention and survival rates. How-
ever, in patients who survived their hospital stay the re-
intervention rate was higher for EVAR than for OR.
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APPENDIX A.
The list of Amsterdam Acute Aneurysm Trial Collaborators is
as follows: centers (number of included patients);
Academic Medical Center (39); R. Balm, M.J.W. Koelemay,
M.M. Idu, C. Kox, D.A. Legemate, L.C. Huisman, M.C.M.
Willems, J.A. Reekers, O.M. van Delden, K.P. van Lienden,
Trial coordinators: L.L. Hoornweg, J.J. Reimerink, S.C. van
Beek.
668 S.C. van Beek et al.Onze Lieve Vrouwe Gasthuis (46); A.C. Vahl, V.J. Leijdek-
kers, J. Bosma, A.D. Montaubanvan Swijndregt, C. de Vries,
V.P.M. van der Hulst, J. Peringa, J.G.A.M. Blomjous, M.J.T.
Visser, F.H.W.M. van der Heijden.
VU-University Medical Center (31); W. Wisselink, A.W.J.
Hoksbergen, J.D. Blankensteijn, M.T.J. Visser, H.M.E. Cove-
liers, J.H. Nederhoed, F.G. van den Berg, B.B. van der Meijs,
M.L.P. van den Oever, R.J. Lely, M.R. Meijerink.
Referring centers;
Sint Lucas Andreas ziekenhuis; A. Voorwinde, J.M. Ultee,
R.C. van Nieuwenhuizen
Slotervaartziekenhuis; B.J. Dwars, T.O.M. Nagy
BovenIJ ziekenhuis; P. Tolenaar, A.M. Wiersema
Ziekenhuis Amstelland; J.A. Lawson, P.J. van Aken, A.A.
Stigter
Waterlandziekenhuis; T.A.A. van den Broek, G.A. Vos
Zaans Medisch Centrum; W. Mulder, R.P. Strating
Spaarne ziekenhuis; D. Nio, G.J.M. Akkersdijk, A. van der
Elst
Regional ambulance services; P. van ExterAPPENDIX B. SUPPLEMENTARY DATA
Supplementary data related to this chapter can be found at
http://dx.doi.org/10.1016/j.ejvs.2015.02.015.REFERENCES
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